Valion Bio, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Valion Bio and Shear Kershman Laboratories completed formulation work on an oral mucosal delivery version of Entolimod using SKL's BioViscid platform, creating a potential second development pathway alongside the injectable program. The needle-free formulation is designed for oral mucosa absorption and could expand deployment during radiological emergencies. Next milestone is demonstrating systemic exposure in bloodstream; Valion estimates oral formulation could require 10–40× more doses than injectable program if deployed to ~3.79 million U.S. military, firefighter, and law enforcement personnel.
Why this rating
Formulation success expands pipeline but remains preclinical; no financials, no partnership consideration disclosed. Moderate advance for $4M company with high technical risk.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.